Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Wikidata - wikimedia - TriplyDB

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

http://www.wikidata.org/entity/Q34104555

about

The emerging role of FTY720 (Fingolimod) in cancer treatment Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Regulation of PP2A by Sphingolipid Metabolism and Signaling The Basic Biology of PP2A in Hematologic Cells and Malignancies PP2A: The Wolf in Sheep's Clothing?Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720.Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast.Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups.Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.Targeting sphingosine-1-phosphate in hematologic malignancies Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress.Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Therapeutic targeting of c-KIT in cancer.Oncogenic properties of sphingosine kinases in haematological malignancies.Protein phosphatase 2A: a target for anticancer therapy.Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and subphenotypes in the Han Chinese population.FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.

P2860

Q26748927-12225A3B-05ED-4D48-BA1A-4C4354B284D0 Q26752430-99437CFB-AC56-413E-AF51-B24BC8E68D12 Q27026038-E51C636D-E3BE-4E45-BD3B-262741DABF35 Q28088697-DBFBECBF-346F-4800-8D31-3CC19A700718 Q28088747-8D1DCAEF-C933-49F4-A616-47EB6D7B7081 Q28483245-A1BD6465-A78D-479E-9882-4A4B8CE7801A Q33767159-4A27D047-1E7A-41AE-9491-48C47F2B3C77 Q34043449-28F0A2A3-D20C-42D2-981D-6BB7F31ABAE3 Q34364844-0A1F2F75-7D88-4110-AEA8-ED1F863EB85C Q34800588-0B2869D3-24D2-4736-924F-1CEFB688AD52 Q35011925-4DCB0464-8C07-496D-9381-236CFCF6278A Q35037262-EB7B268C-9932-49A4-8CF3-E17A94FEEA58 Q35061388-2ECFF510-5844-460B-8702-CF70B3D0A579 Q35184749-5480EBBD-E5DE-4C3B-A685-85CEE26E6BD6 Q35617207-5D4BF9EA-C539-4317-9B48-2C6A9F4CE9D9 Q35675184-72206D61-88EE-474B-AA46-11F3826F88C0 Q35845241-B59A1E4F-7340-4AD4-9467-28730D3A3EF8 Q35859963-23705896-1793-49CC-AF00-1125CE77E4CD Q35953902-DBE9A915-D527-481E-AED6-1C585D569F2D Q36011176-26CF7253-CBF7-4EDD-9F1C-5269ECFB8929 Q36072016-7C2F7EBD-9D6F-4BB1-A723-1BD3982E92C1 Q36602177-3A6989F2-97AA-41E4-A6CE-121314631E76 Q36844274-A9C3204F-DBE6-495E-A54E-53D939F37754 Q37056490-0C07F026-589F-4D5B-9E91-727A76A4AFF5 Q37200863-AAACA2AC-E7DB-427A-991C-8B370045B444 Q37416615-31520080-D921-41E0-A19D-F7946CB4BB4D Q37641562-7DE06BF5-CA04-45CB-801B-804084D1DCA6 Q37707099-92176EE6-6F12-478C-8912-EB81C673D821 Q37708933-6C22F4CB-1B09-4104-AC32-85BE698E5575 Q38057806-7B8D4E40-4D9A-497B-A3DD-57DA63FF59A6 Q38092176-9BEDC4C0-EEAF-450D-8E6D-C89F00D0DAE0 Q38103646-AE81A287-6F78-4D28-AE20-20B90E6DCB83 Q38253011-B01A105C-C3D6-4649-9BF8-579C6B474472 Q38546700-52582534-4E3F-41F5-8298-64499697D30B Q38617799-CB4D6AB7-CE2A-4714-963A-1A1B3560EF37 Q38678579-BB32120F-6D8D-4ECD-A0E1-8F700BD19C9C Q38943724-1A6E1946-5EA1-4641-9D60-50AF664DFB0A Q38987696-9A9522A2-13B9-4DFF-8EE0-B3E745B16D8C Q39114974-C857397D-88BD-417F-A55B-B7481F5EAB72 Q39126141-FEA57BD1-944C-4097-89A9-8AD1CAB18083

P2860

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers

http://www.wikidata.org/entity/Q34104555

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@ast

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@en

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@nl

type

label

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@ast

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@en

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@nl

prefLabel

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@ast

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@en

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@nl

P1433

Q34104555-EA4FA4A6-FA6B-42FA-9AE7-75BF6A780195

P1476

Q34104555-10642473-8819-4F77-822A-59492181E067

P2093

Q34104555-2096A733-0F80-4663-B97A-E49438E99F73

Q34104555-21E2856D-A970-4F97-8FC6-7FBF9188D8DB

Q34104555-272AAF8F-2EB9-4693-806A-33B958238C5C

Q34104555-5790B2B3-B1DC-46F2-94BF-4EB89D7A8801

Q34104555-5C949695-08BA-4B1A-A785-34A766641ABB

Q34104555-6CA52F89-BFA6-417C-842B-C47A57305196

Q34104555-7FF41B80-993E-4487-B03B-295FA69798BD

Q34104555-885F0D33-8E97-4675-BF23-4E58109F8467

Q34104555-8BB2019F-642F-491E-8E54-C2C7166E2B41

Q34104555-AB4BEA5E-F2F0-48AD-957C-D8149314394B

P2860

Q34104555-18D358DF-3B79-4FBC-9957-8D7AE39F9052

Q34104555-1AE33F66-6E03-4EBB-9360-F8D5FC0740B5

Q34104555-1D891201-C923-4737-A413-10FAD635C0E2

Q34104555-2828B727-DBA2-4A50-912D-78CA8111C34C

Q34104555-28B2E0A0-BB18-49A4-9827-E7854E6A1540

Q34104555-2C977FD0-34D0-4FD1-A36C-3802E7EB94F6

Q34104555-2F40939C-CF30-4C59-9C75-E65A6F3001F7

Q34104555-362BB2E5-B53F-4180-B180-91665796991C

Q34104555-3D48BA40-A5CF-4EF6-86C0-00842BBB1304

Q34104555-3F646B30-1EB7-4FA8-B5D4-60D497B00877

P304

Q34104555-EC90834B-119D-4677-82CA-9822BBD6FE3A

P31

Q34104555-167D1BD1-DD13-4A8A-B561-199D5F3EE960

P356

Q34104555-0E030965-938C-4986-BCD2-A66E818BBB79

P407

Q34104555-3EA2DD3E-E19B-4875-82D8-A8507D1B55EA

P433

Q34104555-0408E683-C3E8-4B1A-B689-FC4DE5844561

P478

Q34104555-D40809FD-74D4-4D57-BA84-9BC6DC2C908A

P50

Q34104555-1BBD4BB9-425C-4452-BE1A-6594A8C40F37

P577

Q34104555-4F946F98-99C3-42B4-A049-E1F5EE73041E

P5875

Q34104555-11348AAE-C3BA-458B-B266-3B16B5D5F550

P698

Q34104555-D3568CC4-0BC9-4ADF-B5CD-779DBBF301F2

P932

Q34104555-C7DE97B0-7DB2-41D2-84C3-FCA9D26236AB

P356

0008-5472.CAN-09-2544

P1433

Cancer Research

P1476

Essential requirement for PP2A ...... rategy to treat c-KIT+ cancers

@en

P2093

Alistair T R Sim

http://www.w3.org/2001/XMLSchema#string

Amanda M Smith

http://www.w3.org/2001/XMLSchema#string

Daniel Thomas

http://www.w3.org/2001/XMLSchema#string

Danilo Perrotti

http://www.w3.org/2001/XMLSchema#string

Fiona McDougall

http://www.w3.org/2001/XMLSchema#string

Helen Carpenter

http://www.w3.org/2001/XMLSchema#string

Jason A Powell

http://www.w3.org/2001/XMLSchema#string

Kathryn G Roberts

http://www.w3.org/2001/XMLSchema#string

Leonie K Ashman

http://www.w3.org/2001/XMLSchema#string

Mark A Guthridge

http://www.w3.org/2001/XMLSchema#string

P2860

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Early signaling pathways activated by c-Kit in hematopoietic cells

Identification of specific PP2A complexes involved in human cell transformation

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

The biology of stem cell factor and its receptor C-kit.

P304

5438-5447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-2544

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Nicole M Verrills

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44676085

http://www.w3.org/2001/XMLSchema#string

P698

20551067

http://www.w3.org/2001/XMLSchema#string

P932

2933456

http://www.w3.org/2001/XMLSchema#string